Payment overview · 2025
General Payments
$711.14
48 reported records · 12 companies
Healthcare provider profile · identity verified
Jennifer E Burks, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT SMITH, AR · NPI 1821027160
Verified facts
What the public records show
CMS Open Payments records show Jennifer E Burks, MD received $711.14 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.69 | 20.9% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.08 | 19.3% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.05 | 11.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.15 | 9.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $65.43 | 9.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.87 | 8.0% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.92 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.80 | 5.5% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $19.43 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.80 | 2.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.11 | 2.5% | 1 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $17.81 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $711.14 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.92 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $118.93 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $107.00 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.87 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.93 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.27 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $40.92 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.80 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $11.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 166 |
| Losartan Potassium | Losartan Potassium | 357 | 92 |
| Omeprazole | Omeprazole | 339 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 85 |
| Lisinopril | Lisinopril | 290 | 84 |
| Gabapentin | Gabapentin | 228 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 63 |
| Sertraline Hcl | Sertraline Hcl | 208 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 59 |
| Metformin Hcl | Metformin Hcl | 170 | 47 |
| Meloxicam | Meloxicam | 148 | 40 |
| Lovastatin | Lovastatin | 146 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 35 |
| Potassium Chloride | Potassium Chloride | 143 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 35 |
| Tramadol Hcl | Tramadol Hcl | 125 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 36 |
| Clonazepam | Clonazepam | 113 | 17 |
| Metformin Hcl Er | Metformin Hcl | 112 | 35 |
| Furosemide | Furosemide | 106 | 31 |
| Alendronate Sodium | Alendronate Sodium | 100 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 34 |
| Trazodone Hcl | Trazodone Hcl | 92 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 33 |
| Montelukast Sodium | Montelukast Sodium | 84 | 26 |
| Eliquis | Apixaban | 83 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 17 |
| Farxiga | Dapagliflozin Propanediol | 81 | 21 |
| Ozempic | Semaglutide | 81 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 18 |
| Carvedilol | Carvedilol | 74 | 21 |
| Estradiol | Estradiol | 71 | 27 |
| Allopurinol | Allopurinol | 69 | 16 |
| Bupropion Xl | Bupropion Hcl | 68 | 21 |
| Ezetimibe | Ezetimibe | 67 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 17 |
| Buspirone Hcl | Buspirone Hcl | 61 | 17 |
| Alprazolam | Alprazolam | 59 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Pregabalin | Pregabalin | 49 | 18 |
| Simvastatin | Simvastatin | 49 | 14 |
| Eszopiclone | Eszopiclone | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 11 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Fluconazole | Fluconazole | 24 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Irbesartan | Irbesartan | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $711.14 · 48 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, EVENITY, Heplisav-B, Kerendia, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, VYJUVEK, Wegovy, ZAVZPRET, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error